Division of Intramural Research, National Heart, Lung and Blood Institute/NIH, Bethesda, MD 20892, USA.
Am J Kidney Dis. 2011 Jun;57(6):841-9. doi: 10.1053/j.ajkd.2010.11.022. Epub 2011 Feb 3.
Connective tissue growth factor (CTGF) is involved in the development and progression of kidney diseases, including diabetic nephropathy and kidney fibrosis, but also may have a role in mesangial repair after injury. It is unknown whether, in the general population, urinary CTGF levels are associated with a decrease in estimated glomerular filtration rate (eGFR) to <60 mL/min/1.73 m(2) (ie, development of chronic kidney disease [CKD] stage 3).
Nested case-control.
SETTING & PARTICIPANTS: 100 cases of incident CKD stage 3 and 100 age-and sex-matched controls in the Framingham Heart Study; 141 cases and 135 age-, sex-, and race-matched controls in the Atherosclerosis Risk in Communities (ARIC) Study. Controls had eGFR ≥60 mL/min/1.73 m(2) at follow-up in both studies.
Urinary CTGF concentrations.
Incident CKD stage 3, defined as eGFR <60 mL/min/1.73 m(2).
Stored urine samples from Framingham Heart Study and ARIC were measured for CTGF. Covariates were obtained from Framingham Heart Study and ARIC participant examinations.
In the Framingham Heart Study, the median baseline urinary CTGF concentration was lower in cases (1.35 ng/mL) than controls (2.35 ng/mL; paired t test, P < 0.0001). The multivariable-adjusted OR for incident CKD stage 3 was 0.33 (95% CI, 0.17-0.64; P < 0.001) per 1-standard deviation in log urinary CTGF level after adjustment for CKD risk factors, baseline eGFR, and baseline log urinary albumin-creatinine ratio, with similar results in participants without diabetes (n = 184). Results were not materially different when urinary CTGF level was indexed to urinary creatinine level (multivariable-adjusted OR, 0.34; 95% CI, 0.21-0.56; P < 0.001). A similar, but nonsignificant, trend of risk of incident CKD stage 3 with lower baseline urinary CTGF concentration was observed in an independent case-control study conducted in the ARIC Study, with the strongest results observed in participants free of diabetes. This inverse relationship was robust in meta-analysis of both the overall and diabetes-free groups.
Observational study; causality cannot be inferred.
Lower urinary CTGF concentrations precede the onset of CKD stage 3 in the general population. Further work is required to fully characterize how CTGF level influences risk of CKD.
结缔组织生长因子 (CTGF) 参与肾脏疾病的发生和进展,包括糖尿病肾病和肾脏纤维化,但也可能在损伤后的系膜修复中发挥作用。目前尚不清楚在普通人群中,尿 CTGF 水平是否与估计肾小球滤过率 (eGFR) 下降至<60 mL/min/1.73 m²(即发展为慢性肾脏病 [CKD] 3 期)有关。
巢式病例对照研究。
弗雷明汉心脏研究中的 100 例新发 CKD 3 期病例和 100 例年龄和性别匹配的对照者;动脉粥样硬化风险社区研究中的 141 例病例和 135 例年龄、性别和种族匹配的对照者。在这两项研究中,对照者在随访时的 eGFR≥60 mL/min/1.73 m²。
尿 CTGF 浓度。
新发 CKD 3 期,定义为 eGFR<60 mL/min/1.73 m²。
弗雷明汉心脏研究和动脉粥样硬化风险社区研究中储存的尿液样本用于检测 CTGF。弗雷明汉心脏研究和动脉粥样硬化风险社区研究参与者检查中获得了协变量。
在弗雷明汉心脏研究中,病例组(1.35 ng/mL)的基线尿 CTGF 浓度中位数低于对照组(2.35 ng/mL;配对 t 检验,P<0.0001)。经 CKD 危险因素、基线 eGFR 和基线尿白蛋白/肌酐比值校正后,尿 CTGF 水平每增加 1 个标准差,新发 CKD 3 期的多变量调整比值比为 0.33(95%CI,0.17-0.64;P<0.001),在无糖尿病的参与者中(n=184)也得到了类似的结果。当尿 CTGF 水平与尿肌酐水平相关时,结果没有明显差异(多变量调整比值比,0.34;95%CI,0.21-0.56;P<0.001)。在独立的动脉粥样硬化风险社区研究中进行的病例对照研究中,观察到较低的基线尿 CTGF 浓度与新发 CKD 3 期风险呈负相关趋势,但不具有统计学意义,结果最强的观察到在无糖尿病的参与者中。在对总体和无糖尿病组进行的荟萃分析中,这种反比关系是稳健的。
观察性研究;不能推断因果关系。
在普通人群中,较低的尿 CTGF 浓度先于 CKD 3 期的发生。需要进一步研究以充分描述 CTGF 水平如何影响 CKD 风险。